Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2793)
  2. Meeting Abstract (2524)
  3. Review (119)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5690)
  2. Department of Medicine (5680)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (663)
  5. Michael Morris (587)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (199)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (121)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (394)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (302)

More Publishers

Results (5690)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862)
    Meeting Abstract

    Hussain, M.; Dunn, R.; Rathkopf, D.; Stadler, W.; Wilding, G.; Smith, D. C.; Bradley, D.; Cooney, K. A.; Zweibel, J.; Scher, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach
    Meeting Abstract

    Houk, B. E.; Bello, C. L.; Michaelson, M. D.; Bukowski, R. M.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Motzer, R. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)
    Meeting Abstract

    Halabi, S.; Ou, S.; Vogelzang, N. J.; Scher, H.; Small, E. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A physiologically-based pharmacokinetic (PBPK) and pharmacodynamic (PD) model of docetaxel (Doc) and neutropenia in humans
    Meeting Abstract

    Florian, J. A. Jr; Egorin, M. J.; Zamboni, W. C.; Eiseman, J. L.; Lagattuta, T. F.; Belani, C. P.; Chatta, G. S.; Scher, H. I.; Solit, D. B.; Parker, R. S.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as a predictor of response in head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Dave, A.; Fury, M.; Lee, N.; Stambuk, H.; Wang, Y.; Karimi, S.; Pfister, D.; Koutcher, J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Feldman, D. R.; Kondagunta, G. V.; Ronnen, E. A.; Fischer, P.; Chang, R.; Baum, M.; Ginsberg, M. S.; Ishill, N.; Patil, S.; Motzer, R. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC)
    Meeting Abstract

    Dash, A.; Pettus, J. A. 4th; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Bajorin, D. F.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Circulating tumor cells in patients with castration-resistant metastatic prostate cancer
    Meeting Abstract

    Danila, D. C.; Leversha, M. A.; Gonzalez-Espinoza, R.; Anand, A.; Gu, B.; Gignac, G. A.; Larson, S.; Heller, G.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α)
    Meeting Abstract

    Cella, D.; Li, J. Z.; Cappelleri, J. C.; Bushmakin, A.; Charbonneau, C.; Kim, S. T.; Chen, I.; Michaelson, M. D.; Motzer, R. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Baselga, J.; Ye, Q.; Solit, D.; Norton, L.; Rosen, N.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save